LANA2 Antibody (CM-A807) - BSA Free

Western Blot: LANA2 Antibody (CM-A807) [NB200-167] - Detection of LANA2 in infected lysates (30 ug) using 2 ug/ml of NB 200-167. ECL detection 1.5 minutes. Lane 1: BCBL-1 (KSHV+) Lane 2: BC-1 (KSHV+/EBV+) Lane 3: BCP-1 (KSHV+)

Immunohistochemistry-Paraffin: LANA2 Antibody (CM-A807) [NB200-167] - vIRF3 expression in KS tissues. We obtained KS tissue microarrays from AIDS Cancer Specimen Resource and performed immunohistochemistry, visualized by Aperio F.L. digital pathological scanning. A biopsy sample of KS TMA was stained with anti-LANA. Representative image shows the LANA staining of skin KS lesion. Image collected and cropped by CiteAb from the following publication (//mbio.asm.org/lookup/doi/10.1128/mBio.02217-17), licensed under a CC-BY license.

Immunohistochemistry: LANA2 Antibody (CM-A807) - BSA Free [NB200-167] - vIRF3 expression in KS tissues. We obtained KS tissue microarrays from AIDS Cancer Specimen Resource & performed immunohistochemistry, visualized by Aperio F.L. digital pathological scanning. A biopsy sample of KS TMA was stained with anti-LANA & anti-vIRF3 (CM-A807). Representative images show the LANA staining of skin KS lesion & the vIRF3 staining of skin, tonsil, & mouth KS lesions & positive staining corresponding to either LANA or vIRF3 in total KS biopsy specimens embedded in TMA. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29339432), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

• Reactivity: Hu, Mu, V-Vi
• Applications: WB, ELISA, ICC/IF, IHC, IP, KO
• Clone: CM-A807
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 2.0 mg/ml

LANA2 Antibody (CM-A807) - BSA Free Summary

• Description: Novus Biologicals Knockout (KO) Validated Mouse LANA2 Antibody (CM-A807) - BSA Free (NB200-167) is a monoclonal antibody validated for use in IHC, WB, ELISA, ICC/IF and IP. Anti-LANA2 Antibody: Cited in 14 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Immunogen: Recombinant LANA2 fusion protein.
• Localization: Nuclear
• Specificity: This is specific for KSHV LANA2 (residues 143-310 epitope recognition).
• Isotype: IgG1 Kappa
• Clonality: Monoclonal
• Host: Mouse
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • ELISA 1:100-1:2000
  • Immunocytochemistry/ Immunofluorescence 1:10-1:500
  • Immunohistochemistry 1:10-1:500
  • Immunohistochemistry-Frozen 1:10-1:500
  • Immunohistochemistry-Paraffin 1:10-1:500
  • Immunoprecipitation 1:10-1:500
  • Knockout Validated reported in scientific literature (Golas et al)
  • Western Blot 2-4 ug/ml
• Application Notes: By Western Blot, this antibody recognizes a viral protein in KSHV infected B-cells (~66-70 kDa).

Reactivity Notes

Reacts with viral LANA2 protein and shows no cross-reactivity to cellular proteins. Also reacts with human and mouse viral KSHV proteins.

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.1% Sodium Azide
• Concentration: 2.0 mg/ml
• Purity: Protein G purified

Alternate Names for LANA2 Antibody (CM-A807) - BSA Free

• LANA 2
• LANA-2
• Latency-associated nuclear antigen 2
• vIRF 3
• vIRF3
• vIRF-3

Background

LANA2 (latency-associated nuclear antigen 2; also known as viral interferon regulatory factor 3) is a Kaposi's sarcoma-associated herpesvirus (KSHV) latent protein which is encoded by ORFK10.5 and is exclusively expressed by virus infected B- cells. LANA2 has been shown to be critical in KSHV-mediated tumorigenesis as it inhibits p53 function, dsRNA-activated protein kinase R (PKR)-dependent apoptosis, nuclear factor kB activity, interferon regulatory factor 7-mediated interferon signal transduction and virus-mediated transcriptional activation of the alpha-interferon promoter. LANA2 stabilizes and triggers the induction of HIF-1alpha's transcriptional activity and disrupts PODs (PML oncogenic domains). Moreover, LANA2 has been shown to be required for the survival of primary effusion lymphoma (PEL) cells infected with KSHV alone or dually infected by Epstein-Barr virus (EBV) and KSHV, wherein it shows nuclear and cytoplasmic expression.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for LANA2 Antibody (NB200-167)(14)

Publications using NB200-167

• Okpara MO, Vaaltyn MC, Watson JL et al. Modulators of the Hop-HSP90 Protein-Protein Interaction Disrupt KSHV Lytic Replication. ACS infectious diseases 2024-10-30 [PMID: 39475219]
• Xiang Q, Ju H, Li Q et al. Human Herpesvirus 8 Interferon Regulatory Factors 1 and 3 Mediate Replication and Latency Activities via Interactions with USP7 Deubiquitinase J. Virol. 2018-01-17 [PMID: 29343584] (WB)
• Lee HR, Li F, Choi UY et al. Deregulation of HDAC5 by Viral Interferon Regulatory Factor 3 Plays an Essential Role in Kaposi's Sarcoma-Associated Herpesvirus-Induced Lymphangiogenesis MBio 2018-01-16 [PMID: 29339432] (Virus)
• Zuo J, Hislop AD, Leung C et al. KSHV encoded vIRF3 modulates MHC-II antigen presentation through CIITA dependent and independent mechanisms: implications for oncogenesis. J Virol 2013-02-28 [PMID: 23449805] (WB, Human)
• Marcos-Villar L, Gallego P, Munoz-Fontela C et al. Kaposi's sarcoma-associated herpesvirus lana2 protein interacts with the pocket proteins and inhibits their sumoylation. Oncogene 2013-01-14 [PMID: 23318443] (WB, Human)
• Marcos-Villar L, Campagna M, Lopitz-Otsoa F, Gallego P, Gonzalez-Santamaria J, Gonzalez D, Rodriguez MS, Rivas C. Covalent modification by SUMO is required for efficient disruption of PML oncogenic domains by Kaposi's sarcoma-associated herpesvirus latent protein LANA2. J Gen Virol;92(Pt 1):188-94. 2011-01-01 [PMID: 20881090] (WB, Human)
• Sarek G, Jarviluoma A, Moore HM et al. Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency PLoS Pathog. 2010-03-19 [PMID: 20333249] (WB, Virus)
• Shin, YC et al. Kaposi's sarcoma-associated herpesvirus viral IFN regulatory factor 3 stabilizes hypoxia-inducible factor-1 alpha to induce vascular endothelial growth factor expression. Cancer Res;68(6):1751-9. 2008-03-15 [PMID: 18339855] (ICC/IF, Human)
• Choi UY, Lee JJ, Park A et al. Herpesvirus-induced spermidine synthesis and eIF5A hypusination for viral episomal maintenance Cell reports 2022-08-16 [PMID: 35977517] (WB, Human)
• Moodad S, El Hajj R, Hleihel R et al Lenalidomide in Combination with Arsenic Trioxide: an Effective Therapy for Primary Effusion Lymphoma Cancers (Basel) 2020-09-05 [PMID: 32883022] (WB)
  
  Details:
  Citation using the HRP version of this antibody.
• Golas G, Jang S, Naik N, et al. Comparative analysis of the viral interferon regulatory factors of KSHV for their requisite for virus production and inhibition of the type I interferon pathway Virology 2020-02-15 [PMID: 32056714]
• Liang Q, Chang B, Lee P et al. Identification of the essential role of vBcl2 for KSHV lytic replication J. Virol. 2015-03-04 [PMID: 25740994] (WB)
• Marcos-Villar L, Lopitz-Otsoa F, Gallego P et al. Kaposi's Sarcoma-Associated Herpesvirus Protein LANA2 Disrupts PML Oncogenic Domains Inhibits PML-Mediated Transcriptional Repression of the Survivin Gene. J Virol;83(17):8849-8858. 2009-01-01 [PMID: 19553342]

Review for LANA2 Antibody (NB200-167) (1)

Average Rating: 5

(Based on 1 review)

We have 1 review tested in 1 species: Other.

reviewed by: Verified Customer WB Other 12/12/2014

Summary

• Application: Western Blot
• Sample Tested: See PMID 20333249
• Species: Other